Ovarian Cancer

Floor J. Backes, MD, discusses the consideration of financial toxicity when choosing a PARP inhibitor for a patient with ovarian cancer.

David O’Malley, MD, discusses remaining questions in the ovarian cancer field.

Leigha Senter, MS, LGC, discusses the development of genetic testing in ovarian cancer.

Kathleen Moore, MD, director, Oklahoma TSET Phase I Program, and associate professor, Section of Gynecologic Oncology, Stephenson Cancer Center, discusses treatment for patients with ovarian cancer who progress on a PARP inhibitor.

Placing the results of a single trial in the context of real-world, everyday practice is increasingly difficult because of the number of available options and the absence of studies that directly compare individual strategies.

We traveled to Oklahoma City, Oklahoma, for a State of the Science Summit™ on Ovarian Cancer, which featured insights from the Stephenson Cancer Center faculty.

Leisha A. Emens, MD, PhD, discusses a potential future with immunotherapy in ovarian cancer.